2023
Depressive symptoms and anti-N-methyl-D-aspartate-receptor GluN1 antibody seropositivity in the PROSpective cohort with incident stroke
Sperber P, Gebert P, Broersen L, Kufner A, Huo S, Piper S, Teegen B, Heuschmann P, Prüss H, Endres M, Liman T, Siegerink B. Depressive symptoms and anti-N-methyl-D-aspartate-receptor GluN1 antibody seropositivity in the PROSpective cohort with incident stroke. Brain Behavior & Immunity - Health 2023, 34: 100705. PMID: 38033615, PMCID: PMC10684375, DOI: 10.1016/j.bbih.2023.100705.Peer-Reviewed Original ResearchNMDAR1-ABDepressive symptomsHigh titersIschemic strokeProspective cohortEpidemiological Studies Depression ScaleSevere neuropsychiatric symptomsSevere depressive symptomsAutoimmune encephalitisSeronegative patientsAntibody seropositivityIncident strokeSeropositive patientsNeuropsychiatric symptomsSymptoms yearsPatientsLow titersSymptomsTitersCell-based assaysSeropositivityCohortStrokeCESEncephalitis
2022
Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B)
Sperber P, Gebert P, Broersen L, Huo S, Piper S, Teegen B, Heuschmann P, Prüss H, Endres M, Liman T, Siegerink B. Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B). Journal Of Neurology 2022, 269: 5521-5530. PMID: 35718820, PMCID: PMC9468072, DOI: 10.1007/s00415-022-11203-x.Peer-Reviewed Original ResearchConceptsSeronegative patientsIschemic strokeCognitive functionNMDAR1-ABLow titersHigh titersFavorable cognitive outcomeModerate ischemic strokeAntibody seropositivityProspective cohortReceptor antibodiesSerum titersPatientsSeropositivityCognitive statusStrokeTelephone interviewsInverse probabilityTitersCognitive outcomesCell-based assaysTICSLong termSerostatusResultsData
2021
Donor and Recipient Matching in Facial Vascularized Composite Allotransplantation: A Closer Look at the Donor Pool
Kauke M, Haug V, Obed D, Diehm Y, Tchiloemba B, Safi AF, Pomahac B. Donor and Recipient Matching in Facial Vascularized Composite Allotransplantation: A Closer Look at the Donor Pool. Plastic & Reconstructive Surgery 2021, 148: 194-202. PMID: 34181616, DOI: 10.1097/prs.0000000000008094.Peer-Reviewed Original ResearchConceptsDonor poolHepatitis CUnited NetworkPotential donorsEpstein-Barr virus seropositivityCytomegalovirus-seropositive donorsUnderrepresented patient groupsOrgan Sharing databaseFacial Vascularized Composite AllotransplantationHigh-risk characteristicsVascularized Composite AllotransplantationActual wait timesAllotransplant patientsSeronegative patientsSeropositive donorsMost patientsAllotransplant recipientsPatient characteristicsRecipient matchingSharing databasePositive donorsPatient groupVirus seropositivityOrgan SharingOrgan donors
2019
Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B)
Sperber P, Siegerink B, Huo S, Rohmann J, Piper S, Prüss H, Heuschmann P, Endres M, Liman T. Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B). Stroke 2019, 50: 3213-3219. PMID: 31526121, DOI: 10.1161/strokeaha.119.026100.Peer-Reviewed Original ResearchConceptsSecondary vascular eventsFunctional outcomeVascular eventsHigh titersNMDAR1-ABSeronegative patientsSeropositive patientsFirst strokeLong-term clinical outcomesLong-term functional outcomeCombined end pointRecurrent vascular eventsOutcomes of patientsPoor functional outcomeSub-group analysisOutcomes of interestAnti-NMDAAutoimmune encephalitisCardiovascular riskProspective cohortRankin ScaleHazard ratioClinical outcomesNeuroprotective effectsReceptor antibodies
2001
Clinical and Serological Follow-Up of Patients with Human Granulocytic Ehrlichiosis in Slovenia
Lotrič-Furlan S, Avsic-Zupanc T, Petrovec M, Nicholson W, Sumner J, Childs J, Strle F. Clinical and Serological Follow-Up of Patients with Human Granulocytic Ehrlichiosis in Slovenia. MSphere 2001, 8: 899-903. PMID: 11527800, PMCID: PMC96168, DOI: 10.1128/cdli.8.5.899-903.2001.Peer-Reviewed Original ResearchConceptsHuman granulocytic ehrlichiosisAntibody titersTick biteLong-term clinical consequencesGranulocytic ehrlichiosisIFA antibody titersOnset of feverSerological Follow-UpHigh antibody titersMost time pointsSeronegative patientsSeropositive patientsAdult patientsFebrile illnessPatients 6Initial presentationClinical outcomesAntibody responseClinical evaluationFollow-upReciprocal titersClinical consequencesSerum collectionFirst presentationPatients
2000
p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer
Angelopoulou K, Yu H, Bharaj B, Giai M, Diamandis E. p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. Clinical Biochemistry 2000, 33: 53-62. PMID: 10693987, DOI: 10.1016/s0009-9120(99)00084-3.Peer-Reviewed Original ResearchConceptsAntibody-positive patientsP53 gene mutationsP53 protein accumulationAntibody-negative patientsP53 antibodiesSeronegative patientsGene mutationsP53 accumulationBreast cancerProportion of patientsPrimary breast cancerFormer patient groupP53 protein overexpressionPatient groupAutoantibody generationProtein accumulationImmune responseSuch antibodiesDirect DNA sequencingCorresponding tumorsPatientsImmunofluorometric assayGene abnormalitiesCancerP53 gene
1999
Comparison between a Whole Blood Interferon-γ Release Assay and Tuberculin Skin Testing for the Detection of Tuberculosis Infection among Patients at Risk for Tuberculosis Exposure
Kimura M, Converse P, Astemborski J, Rothel J, Vlahov D, Comstock G, Graham N, Chaisson R, Bishai W. Comparison between a Whole Blood Interferon-γ Release Assay and Tuberculin Skin Testing for the Detection of Tuberculosis Infection among Patients at Risk for Tuberculosis Exposure. The Journal Of Infectious Diseases 1999, 179: 1297-1300. PMID: 10191241, DOI: 10.1086/314707.Peer-Reviewed Original ResearchConceptsTuberculin skin testIFN-gamma releaseTuberculosis infectionWhole-Blood Interferon-γ Release AssayStandard tuberculin skin testInterferon-γ release assaysPercent agreementCulture-confirmed tuberculosisHIV-seropositive subjectsTuberculin skin testingHuman immunodeficiency virusInterferon-gamma releaseIntravenous drug usersSingle blood drawSeronegative patientsTuberculosis exposureSkin testingUninfected personsImmunodeficiency virusSkin testBlood drawUrban BaltimoreDrug usersRelease assaysFurther evaluation
1992
Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection
Selwyn P, Alcabes P, Hartel D, Buono D, Schoenbaum E, Klein R, Davenny K, Friedland G. Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1992, 327: 1697-1703. PMID: 1359411, DOI: 10.1056/nejm199212103272401.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsBacterial InfectionsCandidiasis, OralCD4-Positive T-LymphocytesFemaleFollow-Up StudiesHIV InfectionsHumansLeukocyte CountMaleMultivariate AnalysisNew York CityProportional Hazards ModelsProspective StudiesRacial GroupsSubstance Abuse, IntravenousZidovudineConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionDevelopment of AIDSInjection drug usersBacterial infectionsDisease progressionOral candidiasisVirus infectionSite primary medical careMultiple constitutional symptomsPyogenic bacterial infectionsHIV-seropositive patientsPercentage of CD4Cohort of patientsDiagnosis of AIDSMethadone treatment programsProportional hazards regressionProduct-limit survival analysisIncidence of AIDSPrimary medical careRate of progressionRisk of AIDSSeronegative patientsConstitutional symptomsSeropositive patients
1989
Immunological effects of HIV-1 infection on the humoral response to malaria in an African population.
Wabwire-Mangen F, Shiff C, Vlahov D, Kline R, Serwadda D, Sewankambo N, Mugerwa R, Quinn T. Immunological effects of HIV-1 infection on the humoral response to malaria in an African population. American Journal Of Tropical Medicine And Hygiene 1989, 41: 504-11. PMID: 2683820, DOI: 10.4269/ajtmh.1989.41.504.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdolescentAdultAnimalsAntibodies, ProtozoanAntigens, ProtozoanAntigens, SurfaceCross-Sectional StudiesEnzyme-Linked Immunosorbent AssayFemaleHIV SeropositivityHIV-1HumansMalariaMaleMiddle AgedPlasmodiumPlasmodium falciparumPlasmodium malariaeProtozoan ProteinsUgandaConceptsHIV-1 infectionTrauma patientsClinical AIDSSeronegative patientsAntibody levelsHIV-1HIV-1-seronegative patientsHIV-1 seropositive patientsPolyclonal B cell activationCross-sectional studyHigh malaria transmissionB cell stimulationB cell activationSeropositive patientsImmunodeficiency syndromeMalaria antibodiesHumoral responseImmunological effectsSerological responseStudy groupPatientsCell activationMalaria transmissionControl populationLess antibody
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply